AbbVie and Simcere Zaiming have announced a partnership worth over $1bn to develop an investigational drug candidate for ...

In her first Ask Alex article of the year, Scientific Director, Dr Alexandra Loveday explores the ways our expert writers ...

In 2025, expect to see a continued emphasis on minimizing the environmental footprint of congress booths without compromising ...

In her latest Ask Alex article, Principal Medical Writer, Dr Alexandra Loveday explores modular content and whether it holds ...

Regeneron recently presented five-years results from the phase 3 EMPOWER-Lung 1 trial of Libtayo as a first-line treatment ...

Biogen and Eisai have announced that the US Food and Drug Administration (FDA) has accepted a Biologics License Application ...

Eli Lilly and Alchemab Therapeutics have partnered to develop new therapies for amyotrophic lateral sclerosis (ALS). The ...

In its latest update of AXS-05, Axsome reported that the 295-patient phase 3 ACCORD-2 trial met its primary endpoint, with ...

The phase 3 POETYK PsA-1 trial evaluated the drug in patients who were not previously treated with a biologic ...

Kearney Urology Center in the US has reported a 50% reduction in biopsies since adopting a new prostate cancer blood test with “unprecedented accuracy”. The test, EpiSwitch PSE, is the culmination of ...

Austin Lee Resourcing was founded with a clear sense of purpose to provide a high level service that is efficient, genuine and innovative to both our candidates and our clients. Our objective is to ...

At first glance, translating clinical outcome assessments (COAs) from their original language (most commonly English) to other languages appears to be no more complicated than other trial planning ...